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Endothelial dysfunction
As blood vessels age, they accumulate increasing numbers of senescent cells. Endothelial senescence results in endothelial cell (EC) dysfunction that promotes atherosclerotic vascular disease (Erusalimsky 2009 ). Human blood vessels that contain atherosclerotic plaques have a higher proportion of senescent vascular smooth muscle cells (VSMCs) and ECs, as compared to disease-free vessels (Minamino et al. 2002; Minamino et al. 2003; Vasile et al. 2001) . Senescent ECs have reduced eNOS expression (Hoffmann et al. 2001; Matsushita et al. 2001; Sato et al. 1993) , impaired angiogenic and repair capability (Uraoka et al. 2011 ) and altered metabolism that result in endothelial dysfunction and the progression of vascular disease (Erusalimsky and Kurz 2005; Foreman and Tang 2003) .
EC dysfunction, a major hallmark of vascular disease, results from a combination of metabolic and gene expression changes that leads to decreased angiogenic potential and nitric oxide (NO) production, as well as increased expression of pro-inflammatory and pro-thrombotic mediators (Cooke 2000; Davignon and Ganz 2004; Deanfield et al. 2007 ). Acute injury and chronic stress of ECs over time leads to changes in gene expression, which underlie EC dysfunction (Blann 2003; Thum et al. 2000) . With advancing age, accumulation of damage to ECs causes EC dysfunction and this pro-D r a f t 6 and Ganz 2004; Deanfield et al. 2007 ). Loss of the endothelial NO production triggers VSMC proliferation and migration leading to vessel stenosis. In addition to its essential role in mediating vasorelaxation, constitutive production of NO by the endothelium is also critical for controlling blood coagulation (inhibits platelet aggregation), inflammation (prevents leukocyte adhesion to the endothelium) and maintenance of the endothelial progenitor cell population (Aird 2007) .
In ECs, the major producer of NO is the endothelial nitric oxide synthase (eNOS) enzyme, which is encoded by the nitric oxide synthase 3 (NOS3) gene. NOS3/eNOS knockout mice develop hypertension and are susceptible to thrombosis, stroke and atherosclerosis (Godecke et al. 1998; Huang et al. 1995; Shesely et al. 1996) . The eNOS enzyme converts L-arginine and molecular oxygen into L-citrulline and NO (Kolluru et al. 2010; Qian and Fulton 2013) . NO production is dependent upon both the level of expression and the enzymatic activity of eNOS (Kolluru et al. 2010; Qian and Fulton 2013; Tai et al. 2004) . The expression of the NOS3 gene is regulated at the epigenetic, transcriptional and post-transcriptional levels (Tai et al. 2004 thrombotic (e.g. endothelin-1, plasminogen activator inhibitor-1) and pro-inflammatory (e.g. ICAM-1, VCAM-1, E-selectin) mediators are also features of EC dysfunction (Davignon and Ganz 2004; Deanfield et al. 2007 ). Moreover, both increased ROS and loss of NO induce cellular senescence (Deanfield et al. 2007; Erusalimsky 2009; Lee et al. 1999) . EC senescence causes endothelial dysfunction and thereby promotes vascular disease (Erusalimsky and Kurz 2005; Foreman and Tang 2003) . Thus, factors that negatively influence eNOS transcription and phosphorylation or augment ROS production promote endothelial dysfunction.
Oxidative stress and DNA damage EC ageing is accompanied by the progressive accumulation of oxidative damage to cellular components such as DNA and proteins (Donato et al. 2015) . Oxidative damage occurs when ROS react with these molecules and alters their function. The majority of cellular ROS is produced by mitochondrial respiration, however, ROS can also be generated from eNOS uncoupling (Kolluru et al. 2010 ). ROS-induced DNA damage can cause stress-induced cellular senescence via activation of the p53 pathway (Donato et al. 2015; Rufini et al. 2013 ).
D r a f t 8 ageing and that are typified by vascular pathologies (Ikeda et al. 2016) . These syndromes arise from single-gene mutations that perturb nuclear structure or DNA repair, respectively, ultimately resulting in genomic instability (Ikeda et al. 2016 ).
Hutchinson-Gilford progeria syndrome
HGPS is a rare genetic disorder of accelerated ageing caused by mutations in the Lamin A (LMNA) gene (De Sandre-Giovannoli et al. 2003; Eriksson et al. 2003) . The classical LMNA mutation at codon 608 (G>G) does not affect protein coding, but instead causes alternative splicing of the LNMA transcript that results in the production of a truncated pre-Lamin A protein (known as 'progerin' and 'Lamin A-Δ50') (Eriksson et al. 2003; Ikeda et al. 2016 ). The mutant pre-Lamin A, which lacks a ZMPSTE24 cleavage site, cannot be properly post-translationally processed and consequently, remains farnesylated and nuclear membrane-bound (Ikeda et al. 2016; Navarro et al. 2006 ).
Accumulation of progerin leads to nuclear structure changes including membrane blebs and altered chromatin organization (Ikeda et al. 2016; Navarro et al. 2006 ).
Children with HGPS are diagnosed by a mean age of 3 and have a life expectancy of approximately 13 years of age (Navarro et al. 2006) . These individuals most often succumb to myocardial infarctions or strokes that are caused by accelerated atherosclerosis (Ikeda et al. 2016; Navarro et al. 2006) . While the abundance of atherosclerotic plaque and vascular calcification within the aorta and coronary arteries of individuals with HGPS is variable, the phenotype of these plaques is similar to those observed in the arteries of elderly individuals. However, one notable difference between naturally aged elderly vessels and those from HGPS individuals is the absence of medial thickening in HGPS arteries, presumably due to an increased sensitivity to mechanical strain that reduces VSMCs viability (Varga et al. 2006; Verstraeten et al. 2008) . At the molecular level, cells from D r a f t 9 HGPS individuals also have shorter telomeres than non-affected individuals (Alter et al. 2007; Decker et al. 2009 ).
Mouse models with either mutation of Lmna, or knockout of Zmpste24, experience accelerated ageing (Koks et al. 2016; Varela et al. 2005 
Werner syndrome
Werner syndrome is another genetic disorder of accelerated ageing in which affected individuals develop cardiovascular disease. This disorder is caused by mutations in the WRN gene, which encodes a DNA helicase required for both single and double-strand DNA break repair pathways and results in the loss of genomic integrity (Ikeda et al. 2016; Navarro et al. 2006) . The mean age of diagnosis for individuals with Werner syndrome is 24 years and their average life expectancy is 47 years of age (Navarro et al. 2006) . Not unlike natural ageing, the most common causes of mortality for individuals with Werner syndrome are atherosclerotic cardiovascular disease and cancer (Ikeda et al. 2016; Navarro et al. 2006) . At the cellular level, inhibition of the 53 pathway is observed in cells derived from individuals with Werner syndrome (Blander et al. 1999; Spillare et al. 1999 alterations have yet to be described in these mouse models.
Other mouse models of ageing-related vascular dysfunction
In addition to the aforementioned mouse models, there exists several other genetically modified mouse strains that have shown potential utility for the study of vascular disease and ageing (Harkema et al. 2016; Koks et al. 2016) . While the relatively short lifespan of mice permits the study of ageing, unlike humans, mice have much longer telomeres and do not have a propensity for the development of atherosclerotic vascular disease (Calado and Dumitriu 2013; Russell and Proctor 2006) . Despite these limitations, mouse models have been instrumental in expanding our understanding of ageing and cardiovascular disease, as described below.
The senescence-prone inbred mouse strain (SAMP8) develops premature ageing-related endothelial dysfunction at 6 months of age, which correlates with a loss of eNOS expression in the aorta (Novella et al. 2013) . Furthermore, ECs of cerebral microvessels from SAMP8 mice display increased senescence and reduced SIRT1 expression as compared to the senescence-resistant (SAMR1) mouse strain (Ota et al. 2012) . Not surprisingly, by 6 months SAMP8 mice develop more severe perivascular cardiac fibrosis and diastolic dysfunction than the SAMR1 controls (Reed et al.
2011).
The Col1a1 (r/r) mouse model which produces collagenase-resistant collagen undergoes accelerated ageing (Vafaie et al. 2014 high-fat diet, the atherosclerotic phenotype was exacerbated, leading to coronary artery disease and vascular aneurysms (Kuhlencordt et al. 2001 ).
The link between p53 and ageing was demonstrated by studies using p53 mutant mice which display accelerated ageing phenotypes (Maier et al. 2004; Tyner et al. 2002) . Interestingly, while knockout of p53 in the ApoE-deficient mouse model accelerated atherosclerosis (Guevara et al. 1999) , increased expression of p53 in the ApoE model was not protective against atherosclerosis (SanzGonzalez et al. 2007 ).
Mouse models are important contributors to our understanding of the mechanisms underlying vascular dysfunction. By combining two or more genetic models, much can be learned about the complex interplay between different cellular processes and how they affect the vascular system overall.
Role of p53 and SIRT1 in regulating senescence of the vasculature
The p53 protein functions as a tumour suppressor and it has been determined to be deleted or mutated in at least half of human cancers (Hollstein et al. 1991) . Activation of p53 can be triggered by both replicative stress (shortened telomeres) and by DNA damage. During ageing, stresses such as hyperglycemia, smoking and turbulent flow can increase the levels of ROS in ECs, which can cause targets p53 is SIRT1 (Luo et al. 2001) . The yeast ortholog of SIRT1, Sir2, was discovered to regulate lifespan in yeast in response to caloric restriction (Lin et al. 2002) . SIRT1 was also shown to be a target of the polyphenol resveratrol (Howitz et al. 2003 ). An early study by Ota and colleagues demonstrated that SIRT1 was critical for preventing endothelial dysfunction induced by oxidative stress and this correlated with decreased p53 acetylation (Ota et al. 2007 ). Subsequent studies showed that SIRT1 activation protected against hyperglycemia induced endothelial dysfunction both in vitro and in vivo (Chen, H et al. 2012; Orimo et al. 2009 ). Interestingly, hyperglycemia reduced lifespan in wild-type EC but not in EC that were null for p53 (Orimo et al. 2009) . A recent study demonstrated that turbulent blood flow, a risk factor for development of atherosclerotic plaques, induced endothelial senescence via a p53 dependent pathway and that this process could be blocked by treatment with a SIRT1
activator (Warboys et al. 2014 ). In addition, endothelial senescence in the spontaneously hypertensive rat model was decreased with treatment with a SIRT1 activator. This treatment correlated with a decrease in p53 acetylation and increased NOS3 transcription (Han et al. 2012 ).
Regulation of p53 by SIRT1 is important for the control of cellular senescence in many different tissues including the endothelium (Saunders and Verdin 2007) (Figure 2 ).
Negative regulation of eNOS by p53
In ECs, eNOS is negatively regulated by p53. While, the NOS3 promoter contains a functional regulation of eNOS expression in response to p53 over-expression, suggesting that either p53 regulation of eNOS may be species-specific or it may be altered by cellular context.
Mesenchyme homeobox2
The mesenchyme homeobox genes, MEOX1 and MEOX2, encode a family of homeodomain transcription factors. The MEOX proteins are involved in the proper formation of muscle and bone during embryonic development (Bayrakli et al. 2013; Mankoo et al. 2003) and are important regulators of vascular function in the adult (Gorski and Leal 2003; Gorski et al. 1993; Wu et al. 2005 ).
The MEOX homeodomain transcription factors share a highly conserved homeodomain and partial functional redundancy exists between MEOX1 and MEOX2 during development (Mankoo et al. 2003) ,
suggesting that these proteins regulate the transcription of many common target genes and may also share similar roles in the vasculature. In spite of this, the role of MEOX1 in the vasculature is not well defined.
In the adult vasculature, MEOX2 is expressed in VSMCs and ECs where it inhibits proliferation and induces apoptosis (Maillard et al. 1997; Perlman et al. 1999; Perlman et al. 1998; Smith et al. 1997; Wu et al. 2005) . In rat VSMCs, the expression of MEOX2 mRNA is down-regulated in vitro in response to serum and growth factors, as well as in vivo in response to vascular injury (Gorski et al. 1993; Markmann et al. 2003; Weir et al. 1995) . Over-expression of MEOX2 in VSMCs inhibits cell proliferation (Maillard et al. 1997; Smith et al. 1997 ). This inhibition is due to MEOX2-induced transcriptional up-regulation of the cyclin-dependent kinase (CDK) inhibitor p21 CIP1/WAF1 , decreased CDK2 activity and subsequent cell cycle block in the G1 phase (Smith et al. 1997) . Up-regulation of p21 CIP1/WAF1 expression by MEOX2 was shown to be independent of p53, as MEOX2 was able to increase p21 CIP1/WAF1 transcription and inhibit cell proliferation in p53 deficient mouse embryonic D r a f t 15 fibroblasts (Smith et al. 1997) . MEOX2 over-expression also prevents VSMC migration in response to growth factors (Witzenbichler et al. 1999 ).
Similarly, MEOX2 over-expression in ECs increases p21 CIP1/WAF1 expression and decreases cell proliferation and migration (Chen, Y et al. 2007; Gorski and Leal 2003; Patel et al. 2005 delays cell cycle progression in G1 and induces senescence; however, remarkably MEOX2 expression also increases ECFC migration and enhances network formation in these cells (Gohn et al. 2016) .
We have previously shown that the MEOX proteins activate transcription of the cell cycle inhibitors p21 CIP1/WAF1 and p16 
MEOX2 in HGPS
Microarray analysis has shown that MEOX2 expression is significantly increased in cells from We also observed coordinated decreases in genes associated with angiogenesis, positive cell cycle regulation and pseudouridine synthesis ( Figure 3A , 3B). Inhibition of RNA pseudouridylation can decrease ribosome biogenesis, mRNA splicing and telomerase activity, leading to cell cycle arrest and premature senescence (Meier 2005) . In fact, two of the genes identified as being significantly changed in our array are DKC1 and NOP10, which are components of the telomerase complex and are mutated in Dyskeratosis Congenita, a premature ageing syndrome (Mitchell et al. 1999; Pogacic et al. 2000) .
Thus, it is plausible that MEOX proteins may also be involved in telomere maintenance and accelerated replicative senescence.
Within the enriched gene-sets, direct transcriptional targets were identified by focusing on the genes that were not affected by the expression of a DNA-binding deficient version of MEOX2 (MEOX2 Q235E ) ( Figure 3B ). Senescent ECs have impaired angiogenic capability (Uraoka et al. 2011 ) and decreased NO production (Hoffmann et al. 2001; Matsushita et al. 2001; Sato et al. 1993) , resulting in D r a f t 19 endothelial dysfunction (Erusalimsky and Kurz 2005; Foreman and Tang 2003) . Notably, one of the most significantly down-regulated genes in the angiogenesis gene-set was NOS3 ( Figure 3A , 3B), which encodes eNOS.
Changes in NOS3 mRNA levels ( Figure 3C ) induced by the MEOX proteins correlated with changes in eNOS protein expression ( Figure 3D) The levels of NO produced by eNOS are regulated by phosphorylation (Kolluru et al. 2010 ). In ECs, we observed levels of Thr495 (inactive) and Ser1177 (active) phosphorylation that reflected the total abundance of eNOS protein in response to MEOX overexpression in HUVECs (data not shown).
While cells may be able to temporarily compensate for decreased NO production by increasing active phosphorylation of eNOS, sustained repression of eNOS transcription will ultimately result in a loss of NO production. Regulation of eNOS by MEOX proteins was conserved in other EC types, namely human aortic endothelial cells (HAECs) (data not shown).
Furthermore, both MEOX1 and MEOX2 overexpression, increase p53 protein levels in ECs ( Figure 3E ). Augmented p53 protein may not be due to MEOX induced transcription of p53 mRNA, as
we did not detect any changes in p53 transcript levels by microarray. Thus, MEOX1 and MEOX2, via an unknown mechanism, increase p53 protein synthesis or decrease p53 protein degradation, resulting in higher total cellular levels of p53. As described above, the stability and transcriptional capability of Yokoyama, M., Okada, S., Nakagomi, A., Moriya, J., Shimizu, I., Nojima, A., et al. 2014 . 
